Table 1 The characteristics of 305,644 breast cancer patients
Characteristics | ICC,N(%) | IDC,N(%) | N(%) | P-value |
|---|---|---|---|---|
| Â | 760 (0.2%) | 304,884 (99.8%) | 305,644 (100%) | Â |
Age |  |  |  | < 0.001 |
 < 68 | 499 (65.7%) | 221,196 (72.6%) | 221,695 (72.5%) |  |
 68–78 | 162 (21.3%) | 55,204 (18.1%) | 55,366 (18.1%) |  |
 79+ | 99 (13.0%) | 28,484 (9.3%) | 28,583 (9.4%) |  |
Race | Â | Â | Â | 0.331 |
 White | 601 (79.1%) | 241,929 (79.4%) | 242,530 (79.4%) |  |
 Black | 76 (10.0%) | 33,747 (11.1%) | 33,823 (11.1%) |  |
 Other | 83 (10.9%) | 29,208 (9.6%) | 29,291 (9.6%) |  |
Sex | Â | Â | Â | 0.002 |
 Female | 747 (98.3%) | 302,644 (99.3%) | 303,391 (99.3%) |  |
 Male | 13 (1.7%) | 2240 (0.7%) | 2253 (0.7%) |  |
Marital | Â | Â | Â | 0.082 |
 Married | 421 (55.4%) | 180,589 (59.2%) | 181,010 (59.2%) |  |
 Single | 121 (15.9%) | 46,315 (15.2%) | 46,436 (15.2%) |  |
 Divorced | 218 (28.7%) | 77,980 (25.6%) | 78,198 (25.6%) |  |
Site | Â | Â | Â | 0.200 |
 Other | 299 (39.3%) | 119,554 (39.2%) | 119,853 (39.2%) |  |
 502 | 112 (14.7%) | 37,497 (12.3%) | 37,609 (12.3%) |  |
 503 | 41 (5.4%) | 17,801 (5.8%) | 17,842 (5.8%) |  |
 504 | 262 (34.5%) | 107,370 (35.2%) | 107,632 (35.2%) |  |
 505 | 46 (6.1%) | 22,662 (7.4%) | 22,708 (7.4%) |  |
Laterality | Â | Â | Â | 0.033 |
 Left | 415 (54.6%) | 154,712 (50.7%) | 155,127 (50.8%) |  |
 Right | 345 (45.4%) | 150,172 (49.3%) | 150,517 (49.2%) |  |
Grade |  |  |  | < 0.001 |
 I + II | 705 (92.8%) | 184,512 (60.5%) | 185,217 (60.6%) |  |
 II + IV | 55 (7.2%) | 120,372 (39.5%) | 120,427 (39.4%) |  |
AJCC stage |  |  |  | < 0.001 |
 I | 513 (67.5%) | 148,311 (48.6%) | 148,824 (48.7%) |  |
 II | 208 (27.4%) | 110,720 (36.3%) | 110,928 (36.3%) |  |
 III | 29 (3.8%) | 34,605 (11.4%) | 34,634 (11.3%) |  |
 IV | 10 (1.3%) | 11,248 (3.7%) | 11,258 (3.7%) |  |
T stage |  |  |  | < 0.001 |
 T1 | 578 (76.1%) | 185,375 (60.8%) | 185,953 (60.8%) |  |
 T2 | 152 (20.0%) | 93,007 (30.5%) | 93,159 (30.5%) |  |
 T3 | 20 (2.6%) | 14,938 (4.9%) | 14,958 (4.9%) |  |
 T4 | 10 (1.3%) | 11,564 (3.8%) | 11,574 (3.8%) |  |
N stage |  |  |  | < 0.001 |
 N0 | 632 (83.2%) | 201,664 (66.1%) | 202,296 (66.2%) |  |
 N1 | 103 (13.6%) | 74,583 (24.5%) | 74,686 (24.4%) |  |
 N2 | 18 (2.4%) | 18,517 (6.1%) | 18,535 (6.1%) |  |
 N3 | 7 (0.9%) | 10,120 (3.3%) | 10,127 (3.3%) |  |
M stage | Â | Â | Â | 0.001 |
 M0 | 750 (98.7%) | 293,636 (96.3%) | 294,386 (96.3%) |  |
 M1 | 10 (1.3%) | 11,248 (3.7%) | 11,258 (3.7%) |  |
ER status |  |  |  | < 0.001 |
 Negative | 35 (4.6%) | 65,425 (21.5%) | 65,460 (21.4%) |  |
 Positive | 725 (95.4%) | 239,459 (78.5%) | 240,184 (78.6%) |  |
PR status |  |  |  | < 0.001 |
 Negative | 80 (10.5%) | 96,508 (31.7%) | 96,588 (31.6%) |  |
 Positive | 680 (89.5%) | 208,376 (68.3%) | 209,056 (68.4%) |  |
HER-2 status |  |  |  | < 0.001 |
 Negative | 360 (47.4%) | 134,383 (44.1%) | 134,743 (44.1%) |  |
 Positive | 22 (2.9%) | 28,250 (9.3%) | 28,272 (9.2%) |  |
 Unknown | 378 (49.7%) | 142,251 (46.7%) | 142,629 (46.7%) |  |
Surgery | Â | Â | Â | 0.070 |
 No | 21 (2.8%) | 12,381 (4.1%) | 12,402 (4.1%) |  |
 Yes | 739 (97.2%) | 292,503 (95.9%) | 293,242 (95.9%) |  |
Radiaotherapy | Â | Â | Â | 0.032 |
 No | 363 (47.8%) | 133,868 (43.9%) | 134,231 (43.9%) |  |
 Yes | 397 (52.2%) | 171,016 (56.1%) | 171,413 (56.1%) |  |
Chemotherapy |  |  |  | < 0.001 |
 No | 592 (77.9%) | 165,041 (54.1%) | 165,633 (54.2%) |  |
 Yes | 168 (22.1%) | 139,843 (45.9%) | 140,011 (45.8%) |  |